We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+14.46%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$257M
AUM Growth
-$6.27M
Cap. Flow
-$29.2M
Cap. Flow %
-11.36%
Top 10 Hldgs %
53.62%
Holding
74
New
14
Increased
16
Reduced
17
Closed
18

Top Buys

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$3.75M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.53M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$3.48M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$3.35M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.35M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.04M
2
VTRS icon
Viatris
VTRS
+$5.43M
3
SHPG
Shire pic
SHPG
+$5.4M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$5.01M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
51
DELISTED
Radius Health, Inc.
RDUS
$725K 0.28%
18,799
-96,000
-84% -$3.77M
AERI
52
DELISTED
Aerie Pharmaceuticals
AERI
$718K 0.28%
14,779
-79,043
-84% -$4.31M
DCPH
53
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$478K 0.19%
+25,000
New +$458K
XNCR icon
54
Xencor
XNCR
$2.15B
$413K 0.16%
18,000
– –
MTEM
55
DELISTED
Molecular Templates, Inc.
MTEM
$334K 0.13%
+3,209
New +$277K
ASMB icon
56
Assembly Biosciences
ASMB
$709M
$178K 0.07%
+425
New +$130K
ILMN icon
57
Illumina
ILMN
$34.4B
– –
-14,023
Closed -$2.37M
JAZZ icon
58
Jazz Pharmaceuticals
JAZZ
$16.3B
– –
-27,000
Closed -$4.2M
MGNX icon
59
MacroGenics
MGNX
$260M
– –
-54,000
Closed -$945K
MRUS
60
DELISTED
Merus
MRUS
– –
-60,946
Closed -$966K
PCRX icon
61
Pacira BioSciences
PCRX
$1.03B
– –
-16,000
Closed -$762K
PRTA icon
62
Prothena Corp
PRTA
$467M
– –
-42,000
Closed -$2.27M
VNDA icon
63
Vanda Pharmaceuticals
VNDA
$329M
– –
-62,905
Closed -$1.02M
VTRS icon
64
Viatris
VTRS
$19.4B
– –
-140,000
Closed -$5.43M
PVLA
65
Palvella Therapeutics
PVLA
$2.17B
– –
-1,763
Closed -$712K
ICPT
66
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-11,155
Closed -$1.35M
GBT
67
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-20,500
Closed -$561K
TRIL
68
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-161,069
Closed -$693K
GWPH
69
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-9,200
Closed -$922K
FOMX
70
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-358,975
Closed -$1.67M
KITE
71
DELISTED
Kite Pharma, Inc.
KITE
– –
-22,100
Closed -$2.29M
SHPG
72
DELISTED
Shire pic
SHPG
– –
-32,700
Closed -$5.4M
NDRM
73
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-168,025
Closed -$5.01M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2017 Portfolio in Review

As of Q3 2017, International Biotechnology Trust held 74 positions worth $257M, down 2.4% from $263M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

International Biotechnology Trust withdrew a net $29.2M in Q3 2017, closing 18 positions and reducing 17 holdings. Its most notable exit was Viatris, an estimated $5.43M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Alnylam Pharmaceuticals worth $4.85M.

  • International Biotechnology Trust's largest Q3 2017 buy was Alnylam Pharmaceuticals: 41,300 shares worth $4.85M.
  • International Biotechnology Trust added most to Adamas Pharmaceuticals in Q3 2017, an estimated $3.75M increase.
  • International Biotechnology Trust's biggest Q3 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $7.04M.
  • International Biotechnology Trust fully exited Viatris in Q3 2017, selling an estimated $5.43M.
  • International Biotechnology Trust's ten largest holdings make up 54% of its $257M portfolio in Q3 2017.
  • International Biotechnology Trust opened 14 new positions and closed 18 in Q3 2017.
  • International Biotechnology Trust's portfolio value fell 2.4% quarter-over-quarter to $257M.

Based on International Biotechnology Trust's 13F filing for Q3 2017, filed 2 Mar 2018.